Biorestorative Therapies (NASDAQ:BRTX) Announces Earnings Results, Beats Expectations By $0.01 EPS

Biorestorative Therapies (NASDAQ:BRTX) announced its earnings results on Thursday. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.01, Zacks reports. The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.31 million. Biorestorative Therapies had a negative net margin of 3,088.27% and a negative return on equity of 537.94%.

Biorestorative Therapies Stock Up 1.7%

Shares of BRTX opened at $0.19 on Friday. The company has a market capitalization of $4.90 million, a price-to-earnings ratio of -0.18 and a beta of 0.29. Biorestorative Therapies has a 52 week low of $0.17 and a 52 week high of $2.04. The stock’s 50-day moving average price is $0.25 and its 200-day moving average price is $0.76.

Hedge Funds Weigh In On Biorestorative Therapies

Large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC lifted its holdings in shares of Biorestorative Therapies by 102.4% in the 3rd quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock worth $35,000 after acquiring an additional 12,319 shares during the last quarter. Citadel Advisors LLC acquired a new stake in Biorestorative Therapies in the 3rd quarter valued at approximately $152,000. Finally, DRW Securities LLC acquired a new stake in Biorestorative Therapies in the 4th quarter valued at approximately $55,000. 69.38% of the stock is currently owned by institutional investors and hedge funds.

About Biorestorative Therapies

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.